Toshiaki Tsunenari

TL;DR: This work developed ERY974, a whole humanized immunoglobulin G–structured TRAB harboring a common light chain, which bispecifically binds to GPC3 and CD3 and induced a robust antitumor efficacy even against tumors with nonimmunogenic features, which are difficult to treat by inhibiting immune checkpoints such as PD-1 and CTLA-4.

TL;DR: A new xenograft model of multiple myeloma (MM), where growth is strongly regulated by interleukin-6 (IL-6), was established in severe combined immunodeficiency (SCID) mice, and the usefulness of this model to analyze the pathologic role of IL-6 in MM and the efficacy of targeting the IL-7 receptor in IL- 6-dependent KPMM2 cells is shown.

TL;DR: Monoclonal antibodies that cause cell death from the ligation of CD47 could be novel therapeutic agents for incurable leukemia after further optimization such as humanization or making single chain diabodies.

TL;DR: Various hormone refractory prostate cancer cell models have been established with androgen depletion and have helped to clarify the mechanism for the transition into androgen‐depletion independent status, but the mechanism of bicalutamide resistance remains unclear.

TL;DR: The humanized anti-PTHrP monoclonal antibody (mAb) was effective against bone metastasis by inducing osteogenesis and, therefore, will provide a new treatment option forBone metastasis in breast cancer.